Open AccessIN-VITRO EVALUATION OF DIFFERENT AVAILABLE BRANDS OF DEXLANSOPRAZOLE MR CAPSULES
Author(s) -
Halima Sadia,
Quratulain Pirzada,
Safila Naveed,
Sidra Yasmeen,
Rafia Usman Khan
Publication year - 2020
Publication title -
journal of applied pharmacy
Language(s) - English
Resource type - Journals
ISSN - 1920-4159
DOI - 10.21065/19204159.12.11
Subject(s) - heartburn , gastroenterology , gerd , nerd , medicine , eosinophilic esophagitis , proton pump inhibitor , stomach , ranitidine , pharmacology , reflux , disease
Dexlansoprazole delayed release is a newly developed class of Proton Pump Inhibitor (PPI). The drug is effective in the treatment of erosive esophagitis, maintenance of eosinophilic esophagitis and relief of heartburn. Additionally, it is also beneficial in the treatment of heartburn with symptomatic gastroesophageal reflux disease. The drug offers the advantage of no dosage adjustment in patients with hepatic impairment. Dexlansoprazole inhibits the stomach acid secrection by specific inhibition of the hydrogen-potassium–ATPase in parietal cells of stomach.